Table of Content

1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016 & 2021 & 2027)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts (2016-2027)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends (2016-2027)

2 Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Forecasts by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
2.4.6 India Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2016-2027)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Competition Landscape by Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Sales (2016-2021)
3.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Revenue (2016-2021)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (2016-2021)
3.5 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Type (2016-2021)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2027)
5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Application (2016-2021)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027)

6 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
6.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
6.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2016-2021)
6.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2022-2027)

7 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
7.3.1 Europe 147 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 147 Sales Breakdown by Application (2022-2027)

8 China Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
8.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
8.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
8.2.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
8.2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
8.3.1 China 314 Sales Breakdown by Application (2016-2021)
8.3.2 China 314 Sales Breakdown by Application (2022-2027)

9 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
9.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
9.1.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
9.1.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
9.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
9.2.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
9.2.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
9.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
10.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
10.1.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
10.1.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
10.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
10.2.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
10.3.1 Southeast Asia M Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia M Units Sales Breakdown by Application (2022-2027)

11 India Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
11.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
11.1.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2016-2021)
11.1.2 India Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021)
11.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type
11.2.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2016-2021)
11.2.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2022-2027)
11.3 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application
11.3.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2016-2021)
11.3.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Drugs Business
12.1 Eli Lilly
12.1.1 Eli Lilly Corporation Information
12.1.2 Eli Lilly Business Overview
12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.1.5 Eli Lilly Recent Development
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Corporation Information
12.2.2 GlaxoSmithKline Business Overview
12.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.2.5 GlaxoSmithKline Recent Development
12.3 Astellas Pharma
12.3.1 Astellas Pharma Corporation Information
12.3.2 Astellas Pharma Business Overview
12.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.3.5 Astellas Pharma Recent Development
12.4 Sanofi
12.4.1 Sanofi Corporation Information
12.4.2 Sanofi Business Overview
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.4.5 Sanofi Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Business Overview
12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.5.5 Pfizer Recent Development
12.6 Abbott
12.6.1 Abbott Corporation Information
12.6.2 Abbott Business Overview
12.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.6.5 Abbott Recent Development
12.7 Allergan
12.7.1 Allergan Corporation Information
12.7.2 Allergan Business Overview
12.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.7.5 Allergan Recent Development
12.8 TEVA
12.8.1 TEVA Corporation Information
12.8.2 TEVA Business Overview
12.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.8.5 TEVA Recent Development
12.9 Mylan
12.9.1 Mylan Corporation Information
12.9.2 Mylan Business Overview
12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.9.5 Mylan Recent Development
12.10 Novartis
12.10.1 Novartis Corporation Information
12.10.2 Novartis Business Overview
12.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.10.5 Novartis Recent Development
12.11 Merck
12.11.1 Merck Corporation Information
12.11.2 Merck Business Overview
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.11.5 Merck Recent Development

13 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
13.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
14.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

15 Market Dynamics
15.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
15.2 Benign Prostatic Hyperplasia (BPH) Drugs Drivers
15.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
15.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2016-2021)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2016-2021)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Region (2022-2027)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share Forecast by Region (2022-2027)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Companies (2016-2021)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2016-2021)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2016-2021)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2016-2021)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2016-2021)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2016-2021)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2022-2027)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2022-2027)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2022-2027)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2016-2021)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2016-2021)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2016-2021)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2022-2027)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2022-2027)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2022-2027)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2022-2027)
Table 38. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 42. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 46. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 47. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 48. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 49. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 54. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 55. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 56. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 57. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 58. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 59. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 60. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 61. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 62. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 63. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 64. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 66. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 67. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 68. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 69. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 70. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 71. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 72. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 73. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 74. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 75. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 76. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 78. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 79. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 80. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 81. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 82. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 83. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 84. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 85. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 87. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 91. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 93. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 95. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 97. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 98. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2016-2021)
Table 99. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2016-2021)
Table 100. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2016-2021)
Table 102. India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 103. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 104. India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2022-2027) & (M Units)
Table 105. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2022-2027)
Table 106. India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 107. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 108. India Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2022-2027) & (M Units)
Table 109. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2022-2027)
Table 110. Eli Lilly Corporation Information
Table 111. Eli Lilly Description and Business Overview
Table 112. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. Eli Lilly Recent Development
Table 115. GlaxoSmithKline Corporation Information
Table 116. GlaxoSmithKline Description and Business Overview
Table 117. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. GlaxoSmithKline Recent Development
Table 120. Astellas Pharma Corporation Information
Table 121. Astellas Pharma Description and Business Overview
Table 122. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Astellas Pharma Recent Development
Table 125. Sanofi Corporation Information
Table 126. Sanofi Description and Business Overview
Table 127. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 129. Sanofi Recent Development
Table 130. Pfizer Corporation Information
Table 131. Pfizer Description and Business Overview
Table 132. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 134. Pfizer Recent Development
Table 135. Abbott Corporation Information
Table 136. Abbott Description and Business Overview
Table 137. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 139. Abbott Recent Development
Table 140. Allergan Corporation Information
Table 141. Allergan Description and Business Overview
Table 142. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 144. Allergan Recent Development
Table 145. TEVA Corporation Information
Table 146. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 147. TEVA Description and Business Overview
Table 148. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 149. TEVA Recent Development
Table 150. Mylan Corporation Information
Table 151. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 152. Mylan Description and Business Overview
Table 153. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 154. Mylan Recent Development
Table 155. Novartis Corporation Information
Table 156. Novartis Description and Business Overview
Table 157. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 159. Novartis Recent Development
Table 160. Merck Corporation Information
Table 161. Merck Description and Business Overview
Table 162. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021)
Table 163. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 164. Merck Recent Development
Table 165. Production Base and Market Concentration Rate of Raw Material
Table 166. Key Suppliers of Raw Materials
Table 167. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 168. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 169. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 170. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 171. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 172. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2021 & 2027
Figure 6. Hospitals Examples
Figure 7. Drugstores Examples
Figure 8. Others Examples
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2016-2027) & (US$ Million)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2016-2027)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends Growth Rate (2016-2027) (US$/Unit)
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2016 VS 2021
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2021 VS 2027
Figure 15. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 16. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2016-2027)
Figure 17. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 19. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) and Growth Rate (2016-2027)
Figure 21. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 25. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Global 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs: 2016 & 2020
Figure 28. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 33. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 34. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 37. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 38. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 39. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 40. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 41. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 42. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 43. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 44. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 45. Key Raw Materials Price Trend
Figure 46. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 47. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 48. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed